South Chesapeake Psychiatry

06/18/2026

"Your story matters.

Symptoms rarely exist in a vacuum. Sleep, stress, mood, cycles, medical history, relationships, and daily responsibilities can all affect how a person feels.

That is why a good hormone conversation should include more than a lab value. It should include your lived experience, your timeline, and your goals."

CTA: "If you have been trying to make sense of changes in your body or mood, start by writing down your story."

06/17/2026

Small steps can lead to big change.
BHRT stands for Bioidentical Hormone Replacement Therapy, a clinician-guided approach to hormone care using hormones that are chemically identical to hormones the body naturally produces.

You do not have to figure everything out before asking for help. If your mood, sleep, energy, cycles, or sense of well-being have changed, the first step can simply be a conversation.

At South Chesapeake Psychiatry, BHRT care starts with listening, context, and careful decision-making.

Start with one step.

06/16/2026

Meet Amanda Snow who is passionate about Bioidentical Hormone Replacement Therapy, or BHRT. She is now offering this treatment at Chesapeake Psychiatry

We are doing this because many patients reach midlife feeling dismissed, confused, or told that symptoms are “just aging,” “just stress,” or something they simply have to tolerate. Changes in sleep, mood, energy, focus, cycles, hot flashes, night sweats, libido, and overall sense of well-being deserve a thoughtful clinical conversation.

For years, hormone care has been surrounded by myths and oversimplified messages: that all hormone therapy is the same, that it is always unsafe, that “natural” means risk-free, that symptoms should be ignored unless they are severe, or that one standard plan works for everyone.

We believe the better approach is individualized, evidence-informed, and careful. BHRT should begin with listening, medical history, symptom patterns, risk factors, goals, and appropriate follow-up. It is not about chasing trends. It is about helping patients understand their bodies and make informed decisions with a clinician.

Learn more about our BHRT services here:
https://www.southchesapeakepsychiatry.com/services/bhrt

Top-rated psychiatry in Chesapeake, VA. We offer personalized psychiatric evaluations, medication management & SPRAVATO® treatments for depression, anxiety, ADHD & more. Virtual & in-person. Call: (757) 908-2124

05/30/2026

This week I am heading to Psych Congress Elevate, and I am bringing a question with me that I cannot put down.

We finally have antipsychotics built on new biology. The muscarinic agents are here, more are coming, and for the first time we are starting to learn not just whether they work, but for whom. Some of that early signal is genuinely exciting. Some of it stopped me cold. A real-world analysis suggests the clients least likely to respond may include those with intellectual disability, among the most underserved people in all of psychiatry, and I want to sit with that honestly rather than look away from it.

But here is what I keep coming back to. We are pointing a forty-year-old ruler at a brand-new generation of drugs, and then acting surprised when we cannot see what they do. The biology has moved. The instrument has not. And the people most likely to be misread are the ones already least likely to be heard.

My new edition of The Neuropsychiatry Brief is about that gap, what the latest muscarinic data are telling us, the pipeline coming behind Cobenfy, and why I believe the measurement problem is now the most important problem in schizophrenia care. Link in the comments.

I am heading to Psych Congress Elevate on Monday, and I have been refining a poster I am building for APNA this October in Arizona, one that makes an argument I have been making in this newsletter for quite some time: that we are entering an era of antipsychotics built around different biology, and

05/23/2026

Edition 19 of The Neuropsychiatry Brief is a long one, and I am not apologizing for that because this week I had a lot to say. Usually, I focus on a medication, mechanism, receptor, circuit, clinical trial, or emerging area of neuropsychiatry. This week is different. This week is about the third party in the room: insurance.

It is about prior authorizations, medication denials, specialty pharmacy disruptions, credentialing delays, post-payment audits, and clients being told they cannot have the treatment their clinician believes they need. It is about clinicians spending hours fighting administrative barriers instead of providing care. It is about staff buried under phone calls, appeals, pharmacy issues, and angry clients who often do not realize the office is fighting the same system they are.

And I have had enough.

In this edition, I talk about why I chose not to take insurance in my private practice, the difference between practicing psychiatry with clinical judgment versus cost-containment logic, and the moral injury of knowing what a client needs while watching a payer delay, deny, redirect, or obstruct the plan without carrying the clinical liability.

I am done being quiet about it. If these systems want clinicians to keep absorbing the damage in silence, they are making a mistake. I am bringing the flashlight with one million lumens and pointing it exactly where it needs to go, so I hope they have their sunglasses on. I will write, appeal, file complaints, boost posts, run ads, put up videos, and explain denials in plain language so clients, families, employers, regulators, and policymakers understand what is happening.

Whatever it takes, I will be relentless, because sunlight is not rude, accountability is not aggression, and telling the truth about a broken system is not the problem. The problem is that the system has operated in the dark for far too long.

My hope is that others start becoming comfortable being uncomfortable too. Ask why the medication was denied. Ask who wrote the policy. Ask whether it is evidence-based. Ask who carries responsibility when a denial delays care. Ask why the clinician carries the liability while the payer controls access.

If we are serious about mental health, we have to be serious about the machinery that blocks mental health care. Edition 19 is about that machinery, and I am done letting it run quietly in the background.

We are going to do something different this week. Most editions of this brief begin with a medication, a mechanism, a receptor, a circuit, a trial design problem, or an emerging treatment that may change how we think about psychiatric illness.

04/20/2026

🧠 Myth vs. Fact: Mental Health Edition

❌ MYTH: Medication is a last resort and a sign of weakness.
✅ FACT: Psychiatric medication is a medical treatment — just like medication for blood pressure or diabetes. It helps correct chemical imbalances in the brain so you can function and feel your best.

There is no shame in getting the help you need. We're here whenever you're ready.

📞 (757) 908-2124

04/19/2026

Now accepting new patients in Chesapeake, VA! 🎉

Whether you're dealing with anxiety, depression, ADHD, bipolar disorder, or something else entirely — we're here to help you find a path forward.

✅ Virtual & in-person appointments available
✅ Direct access to your provider
✅ Personalized, unhurried care

📞 (757) 908-2124 | southchesapeakepsychiatry.com

Take steps towards mental wellness with expert psychiatric evaluations and 1-on-1 medication management and treatments. Schedule an Appointment Today!

04/18/2026

GLP-1 agonists may end up forcing psychiatry to confront a reality it has been too comfortable ignoring for too long: the biology of mental illness does not begin and end with monoamines.

For years, most of us thought of this class as living squarely in diabetes and weight management. But the deeper you go into the literature, the harder it becomes to ignore what is happening at the intersection of metabolism, reward circuitry, inflammation, addiction, and mood. These are not side conversations anymore. They are increasingly central ones.

In this edition of The Neuropsychiatry Brief, I take a closer look at why GLP-1 agonists are becoming more relevant to psychiatric practice. That includes their potential role in addressing antipsychotic-associated metabolic burden, the emerging alcohol use disorder signal, and the larger question of whether some of psychiatry’s most interesting future treatments may come from outside traditional psychiatric drug development altogether.

What keeps striking me is that this is really the same lesson we keep running into from different angles. Hormones matter. Inflammation matters. Metabolic dysfunction matters. Reward circuitry matters. The nervous system does not care how neatly we divide specialties. Biology is layered, and our treatment models are going to have to become more layered with it.

The point is not novelty. It is function. If a medication helps reduce craving, softens the metabolic cost of an otherwise effective treatment, or helps restore engagement in a life someone is trying to hold onto, psychiatry should be paying attention.

Edition 14 of The Neuropsychiatry Brief is out now.

https://www.linkedin.com/feed/update/urn:li:ugcPost:7451257360100184064/

GLP-1 agonists may end up forcing psychiatry to confront a reality it has been too comfortable ignoring for too long: the biology of mental illness does not begin and end with monoamines. For years, most of us thought of this class as living squarely in diabetes and weight management. But the deeper...

04/17/2026

It's Friday! 🌟 We want to know — what's ONE thing you do to protect your mental health during a stressful week?

Drop it in the comments below. You might inspire someone who needs it today. 👇

04/15/2026

We founded South Chesapeake Psychiatry because we believe you deserve more than a rushed 15-minute appointment. 🙌

Our initial evaluations are a full 60 minutes — because understanding YOU takes time. Your history, your symptoms, your goals. We don't cut corners.

That's the South Chesapeake difference. Personalized care from providers with 50+ combined years of psychiatric experience, who are available to you by phone and email between appointments.

Follow our page to learn more about what we do and how we can help. 💙